- Title
- RAGE: a new frontier in chronic airways disease
- Creator
- Sukkar, Maria B.; Ullah, Md Ashik; Gan, Wan Jun; Wark, Peter A. B.; Chung, Kian Fan; Hughes, J. Margaret; Armour, Carol L.; Phipps, Simon
- Relation
- British Journal of Pharmacology Vol. 167, Issue 6, p. 1161-1176
- Publisher Link
- http://dx.doi.org/10.1111/j.1476-5381.2012.01984.x
- Publisher
- John Wiley & Sons
- Resource Type
- journal article
- Date
- 2012
- Description
- Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous inflammatory disorders of the respiratory tract characterized by airflow obstruction. It is now clear that the environmental factors that drive airway pathology in asthma and COPD, including allergens, viruses, ozone and cigarette smoke, activate innate immune receptors known as pattern-recognition receptors, either directly or indirectly by causing the release of endogenous ligands. Thus, there is now intense research activity focused around understanding the mechanisms by which pattern-recognition receptors sustain the airway inflammatory response, and how these mechanisms might be targeted therapeutically. One pattern-recognition receptor that has recently come to attention in chronic airways disease is the receptor for advanced glycation end products (RAGE). RAGE is a member of the immunoglobulin superfamily of cell surface receptors that recognizes pathogen- and host-derived endogenous ligands to initiate the immune response to tissue injury, infection and inflammation. Although the role of RAGE in lung physiology and pathophysiology is not well understood, recent genome-wide association studies have linked RAGE gene polymorphisms with airflow obstruction. In addition, accumulating data from animal and clinical investigations reveal increased expression of RAGE and its ligands, together with reduced expression of soluble RAGE, an endogenous inhibitor of RAGE signalling, in chronic airways disease. In this review, we discuss recent studies of the ligand–RAGE axis in asthma and COPD, highlight important areas for future research and discuss how this axis might potentially be harnessed for therapeutic benefit in these conditions.
- Subject
- asthma; chronic obstructive pulmonary disease; neutrophilic airway inflammation; receptor for advanced glycation end products; soluble RAGE; damage-associated molecular patterns; high-mobility group box-1; serum amyloid A
- Identifier
- http://hdl.handle.net/1959.13/1311182
- Identifier
- uon:22164
- Identifier
- ISSN:0007-1188
- Language
- eng
- Reviewed
- Hits: 6136
- Visitors: 6089
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|